Private equity firms play ‘pass the Parexel’ with $8.5bn handover deal
pharmaphorum
JULY 5, 2021
Those big groups have become sought after by investors as they have the capacity to sign lucrative, strategic level agreements with pharma companies, which are increasingly opting to outsource drug development activities so they can focus on discovering, in-licensing and commercialising new therapies.
64 
Let's personalize your content